Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors

European Journal of Pharmacology
H E CriswellGeorge R Breese

Abstract

When tested in rats supersensitive to dopamine agonists, the atypical neuroleptic clozapine displayed pharmacological properties expected of both a D-1 and D-2 receptor antagonist. The locomotor response induced by the D-1 receptor agonist SKF-38393 in neonatal-6-hydroxydopamine (6-OHDA)-lesioned rats was reversed in a dose-related fashion, although a complete blockade of this behavior was not observed indicative for only a partial antagonism of D-1 receptor function. Clozapine also blocked the self mutilation resulting from L-dihydroxyphenylalanine (L-DOPA) administration to neonatal-6-OHDA-lesioned rats, an effect previously linked to D-1 receptor activation. At higher doses, clozapine blocked the locomotor activity elicited by the D-2 agonist LY-171555 in adult-6-OHDA-lesioned rats. Therefore, the action of clozapine on D-1 as well as D-2 receptor-mediated behaviors contributes to its pharmacological effects. The ability of clozapine to stop self-mutilatory behavior in neonatal-6-OHDA-lesioned rats suggests that this drug might be an effective treatment for self-injurious behavior associated with the Lesch-Nyhan syndrome and mental retardation.

References

Jun 11, 1979·Life Sciences·C J Niemegeers, P A Janssen
Jul 23, 1975·Psychopharmacologia·B Costall, R J Naylor
May 1, 1975·Pharmakopsychiatrie, Neuro-Psychopharmakologie·H R BürkiT G White
Jul 11, 1985·European Journal of Pharmacology·G R Breese, R A Mueller
Nov 5, 1985·European Journal of Pharmacology·M Morelli, G Di Chiara
Apr 29, 1987·European Journal of Pharmacology·R E Chipkin, M B Latranyi

❮ Previous
Next ❯

Citations

Jul 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·J P BennettL A Schuh
Jul 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·J M TrugmanG F Wooten
Dec 1, 1995·Journal of Autism and Developmental Disorders·R G HammockW R Levine
Feb 9, 1993·European Journal of Pharmacology·E P PrinssenA R Cools
Jul 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·S M Allen, S N Rice
Sep 1, 1990·Brain Research Bulletin·G R BreeseR A Mueller
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·P J Brent, L A Chahl
Feb 26, 1998·Pharmacology, Biochemistry, and Behavior·S M AllenW M Davis
Dec 1, 2001·Schizophrenia Research·K N R ChengappaN Schooler
Oct 16, 1999·Fundamental & Clinical Pharmacology·I Ninan, S K Kulkarni
Jun 5, 1998·Acta Neurologica Scandinavica·F PierelliC Scoppetta
Oct 14, 2009·Indian Journal of Psychiatry·K Nagaraja RaoShamshad Begum
Feb 15, 2005·Brain Research. Brain Research Reviews·George R BreeseBonita L Blake
Jan 16, 2021·Chemico-biological Interactions·Igor PanticClaude Brodski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
S S MoyGeorge R Breese
Movement Disorders : Official Journal of the Movement Disorder Society
L V MetmanT N Chase
The American Journal on Addictions
William V Bobo, Shannon C Miller
© 2022 Meta ULC. All rights reserved